Quantcast

Latest Takeda Pharmaceuticals U.S.A. Inc. Stories

2014-09-11 08:27:41

New Medication for Obese Adults, or Overweight Adults with at Least One Weight-Related Comorbid Condition DEERFIELD, Ill., and LA JOLLA, Calif., Sept. 11, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for...

2014-09-03 16:29:02

Takeda Stresses Continued Confidence in ACTOS DEERFIELD, Ill. and OSAKA, Japan, Sept. 3, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court...

2014-06-16 12:29:02

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO((TM) )(vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). "We understand how a great need still exists for additional treatment options...

2014-05-20 20:22:08

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio((TM)) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). ( ) "Entyvio is a new option that...

2014-05-15 16:28:57

Takeda Emphasizes Continued Commitment to ACTOS and Patient Safety DEERFIELD, Ill., May 15, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois, before Judge Deborah Dooling and is the fifth ACTOS (pioglitazone HCl) case to reach trial. "We empathize with the Whitlatch family but agree with the verdict," said...

2014-04-08 00:22:26

DEERFIELD, Ill., April 8, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 the jury found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly. The trial began...

2014-02-28 16:23:59

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's Colcrys(®), which is a prescription medicine used in adults to prevent and treat gout flares. Takeda Pharmaceuticals U.S.A., Inc. filed suit against Actavis on February 27, 2014 in the...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'